Botched J&J ($JNJ) trials trigger $130M award for Basilea

Switzerland's Basilea has scored a victory in its bitter fight with Johnson & Johnson ($JNJ). After accusing the pharma giant of botching the pivotal clinical trials for the superbug antibiotic ceftobiprole, triggering a rejection by regulators in the U.S. and Europe, a Dutch arbitration court ordered J&J to hand over $130 million.

The arbitration award comes three months ahead of J&J's deadline for handing back the rights to the antibiotic. And now Basilea is expected to push ahead with trials of its own. Jefferies International analyst Philippa Gardner tells Dow Jones she anticipates the Swiss biotech to mount two clinical trials for the drug, which she expects can garner about $140 million a year in peak sales.

The award marks yet another black eye for J&J, which has had to deal with a series of embarrassing mishaps, including a string of product quality snafus. European regulators slapped down the application for ceftobiprole after its inspectors concluded that the late-stage clinical trials conducted by J&J hadn't been compliant with good clinical practice.

"It's our priority to make this drug available to patients as soon as possible," Basilea CEO Anthony Man told Reuters. The award covers Basilea's lost milestones plus damages.

- read the Basilea release
- get the story from Reuters
- here's the Bloomberg report

Suggested Articles

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.

The platform, which is in use at companies including Agios, enables researchers to simultaneously detect DNA and protein changes in single cells. 

As Urovant gears up for the launch of vibegron, its overactive bladder treatment, it is pushing the same drug through the clinic in other indications.